Table 1.
Description of vaccines.
| Producer | Method | Efficacy | Total Number of Doses | Reference |
|---|---|---|---|---|
| Moderna “mRNA-1273” |
mRNA base 2 doses, 4 weeks apart |
94.1% 2 weeks after 2nd dose |
40 million | [10] |
| Pfizer-BioNTech “BNT162b2” |
mRNA base 2 doses, 3 weeks apart |
95.0% 1 week after 2nd dose |
26 million | [11] |
| Oxford University-AstraZeneca “AZD1222” |
Viral vector base 2 doses, 4 weeks apart |
62.1–90.0% 2 weeks after 2nd dose |
20 million | [12] |
| Johnson & Johnson “Ad26.COV2.S” |
Viral vector base 1 dose |
57.0~72.0% (Overall 66.0%) 4weeks after dose |
6 million | [13] |
| Novavax “NVX-CoV2373” |
Protein-based 2 doses, 3 weeks apart |
89.3% 1 week after 2nd dose |
40 million | [14] |